



an Open Access Journal by MDPI

## Adverse Drug Reactions and Gender Differences

Guest Editors:

**Dr. Concetta Rafaniello**

Department of Experimental  
Medicine, University of Campania  
"L. Vanvitelli", Via Santa Maria di  
Costantinopoli 16, 80138 Naples,  
Italy

**Dr. Annalisa Capuano**

Department of Experimental  
Medicine, University of Campania  
"L. Vanvitelli", Via Santa Maria di  
Costantinopoli 16, 80138 Naples,  
Italy

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editors

In the era of personalized and precision medicine, gender differences continue to be a "grey zone" that requires better definition, especially in terms of drug response and tolerability. Several studies suggest that gender and sex differences could result in different drug tolerability in terms of adverse drug reaction (ADR) frequency and seriousness.

Advances in pharmacology are essential to understand the gender differences associated with pharmacological treatments. Although the data available regarding the impact of gender on the safety profiles of medicinal products shows a prevalence of ADR occurrence amongst females over males, gender-specific pharmacovigilance activities must be undertaken in order to reduce the risks associated with the use of medicinal products and to conduct a risk/benefit assessment in greater detail to elucidate the differences between men and women in terms of pharmacokinetics and pharmacodynamics.

In this Special Issue, experts are invited to submit clinical trial, experimental, original, and review articles that contribute to improving the understanding of the different drug safety profiles related to gender differences.



[mdpi.com/si/59820](https://mdpi.com/si/59820)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)